FORMULATION DEVELOPMENT – In Vitro Diffusion Studies in Transdermal Research: A Synthetic Membrane Model in Place of Human Skin
Vivek Joshi, PhD, David Brewster, and Peter Colonero present data on the applicability of a synthetic membrane (Strat-MTM) for in vitro transdermal diffusion studies in place of human or animal skin as a model.
Suniket Fulzele, PhD; Derek Moe, PhD; and Ehab Hamed, PhD; review the lyophilized wafer technology, specifically Lyoc, that offered the world’s first ODT, ODA Lyoc (sodium saccharinate and flamenol) in 1968.
THERAPEUTIC FOCUS – Therapeutic Advances in Non-Small Cell Lung Cancer: Targeting Activating & Resistant Forms of EGFR & ALK
William C. Shakespeare, PhD, provides a brief review of both targets, including approved agents, mechanisms of resistance, and next-generation agents in development; many designed specifically to target disease-resistant mutations.
Anand Shah, MPharm; Sunny Shah, MPharm; Vipul Patel, MPharm, PhD; and Arti Potdar, MPharm; review the various approaches adapted to nanonize the drug, the characterization of the prepared drug nanoparticles, and their applications.
DRUG DEVELOPMENT – Advancing Personalized Medicine: A Seamless Solution to Discover & Deliver Novel Diagnostic Tests
The use of companion diagnostics in conjunction with custom pharmaceuticals is expected to expand as the promise of personalized medicine continues to be realized. However, a concurrent development cycle of both diagnostic and therapeutic requires a complex synergy of both diagnostic and drug development, and represents a significant deviation from the current pharmaceutical model.
Dr. Marc Mansour, Chief Operating Officer & Chief Science Officer of Immunovaccine, discusses the DepoVax platform and the companyâ€™s clinical trials for DPX-0907 and DPX-Survivac.
EXECUTIVE INTERVIEW – NanoSmart Pharmaceuticals: Patented Delivery Platform Using Human Autoimmune Antibodies to Target Cancers & Other Debilitating Diseases
Dr. James Smith, President of NanoSmart Pharmaceuticals, discusses his company’s innovative approach to drug delivery using immunoliposomes and their unique targeting ability.
FORMULATION DEVELOPMENT – Oral Administration of an Insulin-Soybean Suspension in Streptozocin Rats: Effect of Aqueous Soybean Extract Vehicle
Antoine Al-Achi, PhD; Brijesh Patel, MS; and Sejal Patel, MS; investigate in this study the hypoglycemic activity of an insulin suspension given orally in a vehicle of soybean extract to streptozocin diabetic rats.
BIOAVAILABILITY ENHANCEMENT – A Novel Spray-Drying Technology to Improve the Bioavailability of Biopharmaceutical Classification System Class II Molecules
David Shi, PhD; Andrew Loxley, PhD; Robert W. Lee, PhD; and David Fairhurst, PhD; briefly discuss a proven and scalable solid dispersion approach based on spray-drying that is suitable for BCS Class II APIs and NCEs.
EXCLUSIVE ONLINE CONTENT
STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, recently announced a strategic partnership.
Medherant Limited, the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases using its unique TEPI Patch technology, recently announced a new $2.5-million investment.
Catalent (Booth 3101) recently announced it will launch its new OneBio Suite for the integrated development, manufacturing, and clinical supply of biologic drugs at the…
Cybrexa Therapeutics recently announced preclinical data supporting the potential of its proprietary alphalex technology platform.
HOOKIPA Pharma Inc. recently announced it has achieved a further research milestone in its collaboration and license agreement with Gilead Sciences, Inc. for development of a therapeutic hepatitis B virus (HBV) vaccine.